Identifying patients at risk for recurrent or advanced BCC
Hamid, O.; Goldenberg, G.
Journal of Drugs in Dermatology Jdd 12(11) 1246-1252; Quiz: 1253-1254
2013
ISSN/ISBN: 1545-9616 PMID: 24196332 Document Number: 12991
Basal cell carcinoma (BCC) is a common skin cancer and its incidence is on the rise worldwide. Clinical presentation and histologic examination are used for diagnosis and to stratify BCCs as either low- or high-risk for recurrence or development of advanced disease. A number of surgical and nonsurgical options are available for BCC. BCC is most often managed with a surgical approach, but not all tumors and patients are suitable for surgery. Vismodegib is a recently approved first-in-class hedgehog pathway inhibitor that has expanded options for patients who have locally advanced or metastatic BCC.
Document emailed within 1 workday
